Home › Funds › Spruce Street Capital LP › LXEO

Spruce Street Capital LP position in LXEO

LEXEO THERAPEUTICS INC · Health Care

Spruce Street Capital LP reported holding 928,593 shares of LXEO (LEXEO THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$3.1M, representing 0.50% of its reported portfolio and ranking #35 among its reported holdings. Spruce Street Capital LP has disclosed LXEO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)928.59K sh
Reported value held$3.14M
Portfolio Weight0.50%
First reportedQ4 2025
Last changeHold
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Spruce Street Capital LP's LXEO position evolved

Spruce Street Capital LP first disclosed a stake in LXEO in Q4 2025 at 175,000 shares (US$1.7M). The position peaked in Q1 2026 at 928,593 shares, worth US$5.3M. Across 4 filings, Spruce Street Capital LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 928,593 shares valued at US$3.1M. Notable position changes include a 431% increase in Q1 2026 (shares fell 19% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 175.00K $1.74M New
Q1 2026 928.59K $5.33M Add
Q2 2026 928.59K $4.32M Hold
Q3 2026 928.59K $3.14M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LXEO and 13F data

LXEO (LEXEO THERAPEUTICS INC) is a Health Care company. 37 other funds we track also report a position in LXEO — the largest reported positions include MONTANOVA CAPITAL, LLC (US$29.7M), Affinity Asset Advisors, LLC (US$24.5M), Frazier Life Sciences Management, L.P. (US$22.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LXEO

All LXEO fund holders →

FAQ

How long has Spruce Street Capital LP held LXEO?

Spruce Street Capital LP has disclosed LXEO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Spruce Street Capital LP's current position in LXEO?

As of Q3 2026, Spruce Street Capital LP holds 928.59K shares of LXEO (LEXEO THERAPEUTICS INC), valued at $3.14M, representing 0.50% of its reported portfolio and ranking #35.

Has Spruce Street Capital LP been buying or selling LXEO?

In the latest 13F filing (Q3 2026), Spruce Street Capital LP held unchanged its position in LXEO. The position peaked in Q1 2026 at 928.59K shares.

Which other funds hold LXEO?

Other major institutional holders of LXEO include MONTANOVA CAPITAL, LLC, Affinity Asset Advisors, LLC, Frazier Life Sciences Management, L.P., among 37 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.